Influence of processing variables and in vitro characterization of glipizide loaded biodegradable nanoparticles

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 3, Issue 2, 2009, Pages 113-117

  Jain, Shelesh ^a   Saraf, Swarnlata ^a  

^a PT RAVISHANKAR SHUKLA UNIVERSITY   (India)

Author keywords

Diabetes; Glipizide; Nanoparticles; PLGA NPs; Sustained release

Indexed keywords

GLIPIZIDE; NANOPARTICLE; POLYGLACTIN; POLYSORBATE 80; POLYVINYL ALCOHOL; SOLVENT;

ARTICLE; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG FORMULATION; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; EVAPORATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SURFACE CHARGE; SUSTAINED RELEASE FORMULATION; ZETA POTENTIAL;

EID: 67349211035     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2009.04.003     Document Type: Article

References (21)

1. Arunachalam S., and Gunasekaran S. Diabetic research in India and China today: from literature-based mapping to health-care policy. Curr Sci 9-10 (2002) 1086-1097
2. Nolte M.S., and Karam J.H. Pancreatic hormones and antidiabetic drugs. In: Katzung B.G. (Ed). Basic and clinical pharmacology (2001), Lange Medical Books/McGraw-Hill Publishing Division, New York 711-734
3. Davis S.N., and Granner D.K. Insulin, oral hypoglycemic agents, and the pharmacotherapy of the endocrine pancreas. In: Hardman J.G., and Limbird L.E. (Eds). The pharmacological basis of therapeutics (1996), McGraw-Hill Co., New York 1487-1517
4. U.K. Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. Simonson D.C., Kourides I.A., Feinglos M., Shamoon H., and Fischette C.T. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM-results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 20 (1997) 597-606
6. Riddle M.C., McDaniel P.A., and Tive L.A. Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 20 (1997) 992-994
7. Srinivas M., Udupa N., Kumar S., Agarwal S., Subramanian G., and Ranjith A.K. Glipizide matrix transdermal systems for diabetes mellitus: preparation, in vitro and preclinical studies. Life Sci 79 (2006) 1568-1577
8. Jamzad S., and Fassihi R. Development of a controlled release low dose class II drug-glipizide. Int J Pharm 312 (2006) 24-32
9. Verma R.K., and Garg S. Selection of excipients for extended release formulations of glipizide through drug-excipient compatibility testing. J Pharm Biomed Anal 38 (2005) 633-644
10. Levy J., Vandenberg M., and Grunberger G. Insulin versus glipizide treatment in patients with non-insulin-dependent diabetes mellitus-effects on blood pressure and glucose tolerance. AJH (1995) 8M5-453
11. Rawat M., Singh D., Saraf S., and Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 29 (2006) 1790-1798
12. Jain S., Shukla K., Jain V., Saraf S., and Saraf S. Nanoparticles: emerging carriers for delivery of bioactive agents. Pharma Times 39 (2007) 30-35
13. Cui F., Shi K., Zhang L., Tao A., and Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114 (2006) 242-250
14. Park T.G., Lu W., and Crotts G. Importance of in vitro experimental conditions on protein release kinetics, stability, and polymer degradation in protein encapsulated poly(d,l-lactic-co-glycolic acid) microspheres. J Control Release 33 (1995) 211-222
15. Dashora K., Saraf S., and Saraf S. Effect of processing variables and in vitro study of microparticulate system of nimesulide. Braz J Pharm Sci 43 (2007) 1-8
16. Dashora K., Saraf S., and Saraf S. Effect of processing variables on microparticulate system of aceclofenac. Pak J Pharm Sci 19 (2006) 1-6
17. Liu F.I., Kuo J.H., Sung K.C., and Oliver Y.P. Biodegradable polymeric microspheres for nalbuphine prodrug controlled delivery: in vitro characterization and in vivo pharmacokinetic studies. Int J Pharm 257 (2003) 23-31
18. Devarajan P.V., and Sonavane G.S. Preparation and in vitro/in vivo evaluation of gliclazide loaded eudragit nanoparticles as a sustained release carriers. Drug Dev Ind Pharm 33 (2007) 101-111
19. Haznedar S., and Dortunc B. Preparation and in vitro evaluation of eudragit microspheres containing acetazolamide. Int J Pharm 269 (2004) 131-140
20. Trotta M., Debernard F., and Caputo O. Preparation of solid-lipid nanoparticles by a solvent emulsification diffusion technique. Int J Pharm 257 (2003) 153-160
21. S. Jain, S. Saraf, Preparation and in vitro evaluation of glipizide loaded poly(d,l-lactide-co-glycolide) nanoparticles for effective management of type II diabetes, Nano Sci. Nano Technol. Indian J., Accepted Manuscript No. Na78432748.